Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1

Interventions

Specimen Handling 80Fluorouracil 75Oxaliplatin 67Magnetic Resonance Spectroscopy 61Leucovorin 59Bevacizumab 56Gemcitabine 53Biopsy 41Irinotecan 37Capecitabine 37pembrolizumab 35Cisplatin 35Nivolumab 33Cetuximab 32130-nm albumin-bound paclitaxel 28Paclitaxel 27durvalumab 26atezolizumab 21Folfox protocol 20Radiotherapy 17Carboplatin 17Taxes 16dehydroftorafur 15Radiation 14Cyclophosphamide 14X-Rays 13Albumin-Bound Paclitaxel 13trastuzumab deruxtecan 12fludarabine 12Surgical Procedures, Operative 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
IDRX-42 × Gastrointestinal × 30 days × Clear all
NCT07218926 2026-05-27

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

GlaxoSmithKline

Phase 3 Recruiting
450 enrolled
GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡